IL6 and susceptibility to pneumonia measurement: Retrospectively patients with an IL-6 > 10,000 pg/ml.No difference in IL-6 reduction, hemodynamic stabilization, or mortality in patients with Cytosorb ® treatment compared to a matched patient population.However the underlying diseases resulting in hypercytokinemia were much varied, being separated as sepsis (different reasons except urosepsis) (21.0%), urosepsis (15.2%), septic shock (15.2%), ARDS (13.3%), hemorrhagic shock (8.6%), pneumonia (6.7%), polytrauma (4.8%), and others (15.2%).